In metastatic melanoma patients, the two most promising drugs targeting TGFβ signalling are Fresoluminab (GC1008, Genzyme) and Trabedersen (AP-12009, Antisense Pharma), both targeting the TGFβ ligands. This evidence concerns the gene TGFB1 and metastatic melanoma.